2016 Call for Proposals

Deadline: March 9, 2016

Program

The Wallace H. Coulter Endowment at Duke University provides funding to support collaborative translational research projects that involve co-investigators from the Department of Biomedical Engineering and a clinical department in the School of Medicine. The goal of this program is to support collaborative research that addresses unmet clinical needs and leads to improvements in health care and to commercial products. Examples of desirable outcomes include inventions, patents, improved diagnosis and treatment of disease, follow-on funding (e.g. grants, SBIR, angel investment) commercial products, licenses, commercial partnerships and start-up companies.

Eligibility

Only permanent, full-time, faculty in the professorial ranks (assistant, associate, or full) may apply.

Criteria

Each proposal must have co-PIs, at least one whose primary or secondary appointment is in the Department of Biomedical Engineering and at least one clinical investigator from the Duke University School of Medicine. The research must relate directly to applications in health care, and the objectives of the project should include an outcome that will benefit patients. Evaluation of each proposal will be on the basis of scientific merit, potential health care impact and significance, experience of the investigators, the potential for commercialization or translation to patient care and for successfully obtaining further support.

Submission

Coulter Grant Submission Guidelines: Download [PDF, 442kb]

General questions about proposals and review process, as well as specific questions about scientific content or commercialization strategy should be addressed to Barry Myers (919-681-7552; barry.myers@duke.edu) before submission. We strongly recommend submitting a brief summary (less than one page) in January 2016.  Provide project title, team members, project goals and an initial assessment of potential users of the technology.

Submit the summary via email to Barry Myers (barry.myers@duke.edu and Lynn Sutton (lynn.sutton@duke.edu).  The summary will be used for evaluation of potential impact on patient care and the commercialization strategy that needs to be employed to get there. Feedback will be provided to project teams.

Proposals must follow the Coulter Grant Submission Guidelines.  Proposals wll be rejected if any component is missing.  Submit proposals by Wednesday, March 9, 2016 via Duke's MyResearchProposal online application software.  To apply:

  • Visit http://bit.ly/myresearchproposal and log in if you already have an account or select “Create New User". Proposals must be submitted under one of the Principal Investigator's names.
  • Enter access code "DTRI" and select the "Coulter Translational Research Partnership 2016" funding opportunity and follow the instructions.
  • A step-by-step user's guide for applying via the MyResearchProposal software is available.

An Oversight Committee will review proposals and make recommendations on funding priority. Selection of finalists for oral presentations will occur in April 2016. Oral presentations will be scheduled for May 2016 and awardees will be notified shortly thereafter. Grant awards begin September 2016.

We strongly encourage all applicants to work closely with Barry Myers during the proposal preparation period. Our team helps all applicants understand the review criteria, components of the proposal and write the most competitive application.

Duration

Award recipients will be required to prepare brief written quarterly progress reports.  Grants will be for a one-year period, and may be submitted for renewal. Renewal applications must have a comparison of milestones achieved vs. those planned in the original submission. Renewal applications will be evaluated on a competitive basis with new applications.

Oversight Committee

  • Ashutosh Chilkoti, PhD, Chairman and Professor, Biomedical Engineering, Coulter Translational Partnership Grant PI
  • Victoria Christian, COO of Duke Translational Research Institute, Duke Translational Medicine Institute
  • Michael Hill, PhD, Vice President, Research and Development, Medtronic
  • Robert Morff, PhD, Venture Partner, Hatteras Ventures
  • Barry Myers, MD, PhD, MBA, Professor of Biomedical Engineering, Coulter Program Director, Director of Emerging Programs, Duke Translational Research Institute, Ex officio
  • James Rosen, MBA, Deputy Director of Program Related Investments, Bill and Melinda Gates Foundation
  • Kevin A. Schulman, MD, Professor of Medicine, Duke University School of Medicine, Professor of Business Administration, The Fuqua School of Business, Duke University,Director, Duke Clinical Research Institute
  • Mark Stacy, MD, Vice Dean for Clinical Research and Professor of Neurology, Duke University School of Medicine
  • John Sundy, MD, PhD, Vice President, Inflammation and Respiratory Therapeutics, Gilead Sciences, Inc.